Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study.

ABSTRACT:

Purpose

This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea.

Materials and methods

Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response.

Results

Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free surviva

SUBMITTER: Choi YS 

PROVIDER: S-EPMC11729325 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature